These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. The trials and tribulations of pediatric drug trials. Shinnar S; Pellock JM Neurology; 2005 Nov; 65(9):1348-9. PubMed ID: 16275818 [No Abstract] [Full Text] [Related]
31. Impact of the "French Levothyrox crisis" on signal detection in the World Health Organization pharmacovigilance database. Khouri C; Revol B; Lepelley M; Mallaret M; Cracowski JL Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1427-1428. PubMed ID: 30379373 [No Abstract] [Full Text] [Related]
35. The first report of oxcarbazepine-induced vanishing bile duct syndrome. Tekin F; Celik F; Nart D; Akarca U J Gastrointestin Liver Dis; 2014 Jun; 23(2):222-3. PubMed ID: 24949618 [No Abstract] [Full Text] [Related]
36. [Low serum free thyroxine concentration in a patient treated with oxcarbazepine]. Ronzón-Fernández A; Maciá-Bobes C Rev Neurol; 2006 Apr 1-15; 42(7):444. PubMed ID: 16602064 [No Abstract] [Full Text] [Related]
37. Adverse drug reaction reporting and pharmacovigilance of new therapeutic agents. Haas SJ South Med J; 2006 Apr; 99(4):325-6. PubMed ID: 16634234 [No Abstract] [Full Text] [Related]
38. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Mogensen PH; Jórgensen L; Boas J; Dam M; Vesterager A; Flesch G; Jensen PK Acta Neurol Scand; 1992 Jan; 85(1):14-7. PubMed ID: 1546529 [TBL] [Abstract][Full Text] [Related]